Inverness expands with HemoSense deal
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations (Waltham, Massachusetts) has entered into a definitive agreement to purchase point-of-care diagnostic company HemoSense. The all-stock deal, which is subject to shareholder approval and is expected to close in the fourth quarter of 2007, will see each holder of a HemoSense share receive 0.274192 shares of Inverness common stock - an approximate 38% premium over the average trading prices of both companies for the last five trading days.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.